Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1

Peter D. Kwong, John R. Mascola, Gary J. Nabel

Research output: Contribution to journalArticle

Abstract

The development of a highly effective AIDS vaccine will likely depend on success in designing immunogens that elicit broadly neutralizing antibodies to naturally circulating strains of HIV-1. Although the antibodies induced after natural infection with HIV-1 are often directed to strain-specific or nonneutralizing determinants, it is now evident that 10%-25% of HIV-infected individuals generate neutralizing antibody responses of considerable breadth. In the past, only four broadly neutralizing monoclonal antibodies had been defined, but more than a dozen monoclonal antibodies of substantial breadth have more recently been isolated. An understanding of their recognition sites, the structural basis of their interaction with the HIV Env, and their development pathways provides new opportunities to design vaccine candidates that will elicit broadly protective antibodies against this virus.

Original languageEnglish (US)
JournalCold Spring Harbor perspectives in medicine
Volume1
Issue number1
DOIs
StatePublished - Sep 2011
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1'. Together they form a unique fingerprint.

  • Cite this